Slow, progressive myopathy in neonatally treated patients with infantile-onset Pompe disease: a muscle magnetic resonance imaging study by unknown
RESEARCH Open Access
Slow, progressive myopathy in neonatally
treated patients with infantile-onset Pompe
disease: a muscle magnetic resonance
imaging study
Steven Shinn-Forng Peng1, Wuh-Liang Hwu2,3,4, Ni-Chung Lee2,3,4, Fuu-Jen Tsai5, Wen-Hui Tsai6
and Yin-Hsiu Chien2,3,4*
Abstract
Background: Patients with infantile-onset Pompe disease (IOPD) can be identified through newborn screening, and
the subsequent immediate initiation of enzyme replacement therapy significantly improves the prognosis of these
patients. However, they still present residual muscle weakness. In the present study, we used longitudinal muscle
magnetic resonance imaging (MRI) to determine whether this condition is progressive.
Materials and methods: A cohort of classic IOPD patients who were diagnosed through newborn screening were
treated with recombinant human acid α-glucosidase (rhGAA) and followed prospectively from birth. The trunk (and
abdominal wall), pelvis and upper thighs were scanned for muscle MRI every 2–3 years. Seven groups of muscles
were individually scored from 0 to 4 based on the extent of their involvement, and the sum was correlated to the
clinical manifestations.
Results: Twenty-four MRI scans from a total of 12 neonatally treated IOPD patients were analyzed in the present
study. The median age at the time of MRI scanning was 4.2 years (13 days to 9 years). High intensity over the
quadriceps on T2-weighted and short-tau inversion recovery images was observed in all scans and was followed by
a decrease in muscle mass. Trunk muscle involvement was slower, except in one patient who exhibited progressive
psoas atrophy. Among the 10 patients for whom follow-up scans were repeated more than 2 years after the first
scan, four patients (40 %) showed increased myopathy severity.
Conclusion: This prospective muscle MRI study provides evidence for the occurrence of slow, progressive muscle
damage in neonatally treated IOPD patients during childhood. New treatment strategies are necessary to improve
outcomes in these patients.
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Background
Pompe disease is a lysosomal storage disorder in which a
deficiency of acid α-glucosidase (GAA, EC 3.2.1.20)
causes the intralysosomal accumulation of glycogen in
all tissues, most notably in skeletal muscles [1]. Enzyme
replacement therapy (ERT) with recombinant human
GAA (rhGAA) [2, 3] is currently the only causal treat-
ment available for patients with Pompe disease. How-
ever, muscle involvement does not respond well to ERT.
It has been suggested that late treatment does not rescue
damaged muscles, and glycogen clearance was observed
in nearly all tissues from two patients who received early
ERT and exhibited good clinical responses at 96 and
77.5 months after the start of ERT [4].
To achieve early diagnosis and treatment, we initiated
a large-scale population newborn screening program
for Pompe disease in 2005 [5]. This program success-
fully identified patients with classic infantile-onset
Pompe disease (IOPD), but also patients with late-onset
Pompe disease (LOPD). The benefits of ERT in classic
IOPD patients who were identified through newborn
screening and treated since birth have been demon-
strated in both survival and ventilation-free survival [6].
However, pelvic girdle weakness gradually developed in
these patients after two years of age and was associated
with an increase in creatine kinase (CK) levels [6]. Ele-
vations in CK levels have been associated with in-
creased urinary glucose tetrasaccharide (Glcα1-6Glcα1-
4Glcα1-4Glc, Glc4) excretion [7], indicating worsening
glycogen accumulation in the muscles [8]. In neonatally
treated IOPD patients, quadriceps biopsies obtained at
6 months after the onset of ERT revealed significant
glycogen clearance [9, 10]; however, follow-up biopsies
are rarely performed because the procedure is invasive.
In addition, muscle biopsy provides only localized
information. Recently, magnetic resonance imaging
(MRI) has shown initial success in detecting abnormal-
ities in multiple muscle groups that are frequently in-
volved in late-onset Pompe disease [11], even before
physical examination [12], and these measurements
could serve as indicators of disease progression. In the
present study, we employed MRI to monitor the pro-
gression of myopathy in a prospective study involving
neonatally treated patients with classic IOPD.
Methods
Patients were selected using a newborn screening pro-
gram directed through the National Taiwan University
Hospital Newborn Screening Center, and the clinical in-
formation has been previously reported [6]. Patients
were numbered by previous studies that NBS indicates
classic IOPD detected by screening, NBSL indicates
LOPD detected by screening, and CLN indicates clinic-
ally diagnosed patients. NBS patients were treated with
20 mg/kg of rhGAA every 2 weeks starting from age 6–
39 days, and the follow-up period was 28–90 months
[6]. Due to persistent elevation of CK and slow improve-
ment in motor development, inadequate muscle treat-
ment efficacy was suspected; therefore, increasing the
dosage and/or frequency was attempted at various ages.
Patients with LOPD were also selected during the same
period and four were included for comparison [13, 14].
All patients participated in a long-term prospective
follow-up study for Pompe disease that was approved by
the local ethics committee, and written informed con-
sent was obtained from the parents.
All patients were followed since birth. One IOPD diag-
nosed by clinical symptoms (CLIN3) but not NBS was also
included in the follow-up program and his data was also
included. For the IOPD patients, muscle MRI of the
trunk (including the abdominal wall), pelvis and upper
thighs was performed approximately every 2 to 3 years.
For classification, patient age at the time the MRI was
performed was categorized as infancy (under 1 year),
toddler (under 4 years), preschool (under 6 years), and
child (over 7 years). MRI was performed using a 1.5-
Tesla scanner (Signa HDXt; GE Medical Systems,
Milwaukee, WI, U.S.A.) (n = 10) or a 3-T MRI system
(Siemens Healthcare, Erlangen, Germany) (n = 2) with an
8-channel, phased-array torso. All uncooperative pa-
tients received chloral hydrate (prepared at National
Taiwan University Hospital) per os at a dose of 0.5-
0.7 mg/kg BW 10–45 min prior to MR examination.
Fast spin-echo T2-weighted images (T2WIs) were col-
lected using the following parameters: long TR, fast
spin echo (TR/TE = 3067-8000/78-100 ms) with a flip
angle of 90–150, echo-train length of 15–20, and acqui-
sition in one axial plane. Spin-echo T1-weighted images
(T1WIs) were obtained using the following parameters:
short TR, fast spin echo (TR/TE = 540-767/9.8-20 ms)
with a flip angle of 90, echo-train length of 3, and one
acquisition in both axial planes. In addition, all patients
also received short-tau inversion recovery (STIR) MRI
examinations using the following parameters: long TR
(TR/TE/TI = 3000-6317/30-90/150-200 ms) with a flip
angle of 90–150, echo-train length of 10, and acquisi-
tion in one coronal plane. The imaging matrix was 256
x 192 or 256 pixels for the T2WIs, T1WIs and STIR
images. The slice thickness for the T2WIs and T1WIs
was 4–5 mm with an intersection gap of 1 mm. Total
scanning time per patient was 30–40 min.
Abnormalities in the trunk, pelvic and upper thigh
muscles were described first. To enable better compari-
sons, especially long-term comparisons, the severity of
muscle involvement was scored for each muscle using a
4-point classification system: (1) normal appearance;
(2) mild involvement (involvement of less than 50 % of
the area); (3) moderate involvement (involvement of
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more than 50 % of the area; and (4) severe involvement,
including fatty replacement or atrophy [15]. Seven mus-
cles were scored, including the erector spinae, psoas,
gluteal, rectus femoris (RF), vastus lateralis (VL), vastus
intermedius (VI), and adductor magnus muscles. The
severity scores were correlate with serum CK and
Pompe-PEDI (Pediatric Evaluation of Disability Inven-
tory specific for Pompe disease) mobility normative
scores using Spearman’s correlation (SPSS software,
version 17.0 for Windows). The Pompe-PEDI [16] was
used to assess the motor capability required for partici-
pating in daily locomotion and transfer tasks, and the
normative standard scores (adjusted for the child’s
chronological age) of the mobility domain of the
Pompe-PEDI Functional Skills Scales were used. Higher
scores reflect a superior capability. The values below
limit of qualification of Pompe-PEDI mobility norma-




Twenty-four MRI scans were obtained from a total of 12
patients in the present study; 2 patients received one
MRI scan, 8 patients received two MRI scans, and 2 pa-
tients received 3 MRI scans (Table 1). These patients
have been previously described [6, 17]. All of the pa-
tients tested positive for cross-reactive immune material
(CRIM), and none of the patients exhibited sustained
high titers of anti-rhGAA. The median age at the time
of MRI scanning was 4.2 years, with the first MRI scan
performed at 13 days to 6 years of age, and the latest
performed at 7 months to 9 years of age. Five MRIs
were performed in the infancy age group (from 4 out of
the total 12 patients; 33 %), while 8 (67 % of patients)
were performed in the toddler, 7 (87.5 %) in the pre-
school, and 4 (67 %) in the child age groups. In this
study, the median age of the tested patients was
7.6 years (2.8-9.2), and all individuals walked independ-
ently. The median CK level at the time of MRI was
1025 U/L (range 198–2500). Four LOPD patients who
were identified through this newborn screening pro-
gram were included for comparison; three patients pre-
senting with persistent CK elevation or frequent falls
were undergoing ERT.
MRI changes during infancy
All patients with IOPD presented with CK elevation
and muscle glycogen accumulation at the time of diag-
nosis. MRI scans were obtained from one patient at
13 days and 7 months of age (Fig. 1). At 13 days of age,
although her muscle biopsy revealed intracytoplasmic
vacuoles in more than 90 % of the myocytes, there were
no signal changes on the T1WIs. Nevertheless,
consistent hyperintensity was detected in the thigh
muscles on STIR images and T2WIs, and this effect
was more prominent in the VL. After ERT for 7 months,
a repeat MRI revealed hyperintensity on T2WIs and
STIR images but not on T1WIs.
T1WI-negative changes during early childhood
The hyperintensity observed in T2WIs and STIR images
persisted in older patients (Fig. 2). At one year of age,
NBS10 presented hyperintensity over the anterior region
of the thigh, particularly in the VI, on T2WIs but not on
T1WIs. At age 3, the lesions on VI were decrease. Those
on the VL appeared only on STIR images, and those on
the RF were detected on both T1WIs and T2WIs. At
1 year of age, an increase in intramuscular fat was also
observed, suggesting a decrease in muscle mass.
T1WI-positive changes in childhood
The older patients presented more extensive changes. In
addition to hyperintensity in T1WIs and T2WIs over the
anterior region of the thigh, other thigh muscles were
also affected, such as the adductor magnus and semi-
membranosus muscles. In addition, the muscle mass
was decreased, as shown using small quadriceps calibers,
and the subcutaneous fat was significantly increased
(Fig. 3). T1WI hyperintensity was also evident as early as
3 years of age in NBS12 (Additional file 1: Figure S1).
All patients presented thin rectus abdominis muscles, with
some hyperintensity in the external and internal oblique
muscles and the transversus abdominis muscle. The trunk
(psoas, iliocostalis, longissimus and multifidus muscles)
and gluteal muscles were more gradually affected than the
thigh muscles (Additional file 2: Figure S2).
Among the examined muscles, the progression of the
psoas muscles varied (Additional file 3: Figure S3). For
example, psoas muscle atrophy was observed upon the
first examination of NBS3, who could barely stand
straight, likely because of prior fat infiltration in the
psoas muscles, as demonstrated in NBS2 at 8 years of
age and in NBS12 at 3 years of age.
Progression of myopathy
We therefore scored the severity of the commonly af-
fected muscles, including the erector spinae, psoas, glu-
teal, RF, VL, VI, and adductor magnus muscles (Table 1).
Point totals that exceeded 7 were considered abnormal.
Among the 10 patients for whom at least one follow-up
scan was obtained at least 2 years after the first scan, the
scores of 4 patients (40 %) showed deterioration with
age, of 2 patients (20 %) showed improvement with age,
and of 4 patients (40 %) remained stable, although
NBS4’s images showed more extensive changes (Fig.3a
and Additional file 4: Figure S4). The two patients with
decreased scores were NBS9 and NBS10. NBS10 was
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administered treatment at 6 days of age, and NBS9, who
was born prematurely, was administered treatment at
35 weeks post-conception. These two patients also
had higher rhGAA dosages at the time of the second
scans. In addition, some of the other patients were
receiving higher rhGAA dosages at the time of the
second scan or had received an increase in dosage
between the 2 scans, but we could not correlate the
potential benefits of a higher rhGAA dosage with the
MRI changes observed in our study because the
follow-up protocol was not designed to evaluate the
effects of dose changes. The severity scores were






GAA gene Each MRI scan
Mutation 1 Mutation 2 Age (yr) MRI Score CK (U/L) Mobility scores
NBS2 26 D 9.2 c.1935C > Ab c.1411_1414delc 4.9 17 595 20.2
8.1 24 2500 <10
NBS3 29 D 9.1 c.1935C > A c.2842insT 4.0 19 2135 18.46
5.8 23 2444 <10
8.0 25 1957 <10
NBS4 17 D 8.5 c.1935C > A c.784G > A 6.3 22 1642 12.12
8.4 22 1674 22.51
NBS5 34 D 8.0 c.1935C > A c.1935C > A 2.9 15 1238 33.33
4.9 21 1663 26.05
NBS6 12 D 7.6 c.1935C > A c.[1062C > G; 1286A > G] 2.5 18 735 35.89
6.1 18 596 21.88
NBS8 14 D 6.2 c.1935C > A c.1197_1208del 6.2 21 1156 4.64
NBS9 39 D 5.9 c.1935C > A c.2040 + 1G > T 0.6 12 198 32.90
4.4 9 1030 30.83
NBS10 6 D 4.5 c.1935C > A c.1935C > A 1.0 14 733 44.05
3.0 12 1020 58.89
NBS11 14 D 4.4 c.1935C > A c.1935C > A 3.0 16 941 30.06
NBS12 16 D 4.1 c.1935C > A c.1197_1208del 1.3 18 246 24.44
3.1 22 673 24.53
NBS14 10 D 2.8 c.1935C > A c.1935C > A 0.0 - 637 -
0.6 16 344 -
3.1 15 760 -
CLN3 3 M 9.0 c.1935C > A c.1411_1414delc 6.5 20 1904 26.87
9 19 1565 24.40
NBSL2 3 Y 8.4 c.2238G > C c.2662G > T 1.5 11 267 52.19
7.3 11 267 38.74
NBSL6 3.5 Y 7.7 c.1935C > A c.[752C > T; 761C > T] 2.7 7 113 39.85
5.8 7 222 37.85
NBSL12 - 6.4 c.1935C > A c.[752C > T; 761C > T] 3.5 7 87 60.99
NBSL16 4 M 4.6 c.1935C > A c.1634C > T 0.4 7 861 -
3.3 7 173 53.03
D days, M months, Y years; MRI score: MRI severity scores from seven groups of muscles; Mobility scores: Pompe PEDI (Pediatric Evaluation of Disability Inventory
specific for Pompe disease) mobility normative scores
aPatients were numbered by previous studies that NBS indicates classic IOPD detected by screening, NBSL indicates LOPD detected by screening, and CLN
indicates clinically diagnosed patients
bThis mutation is always associated with the c.1726G > A mutation
cThis mutation is associated with the c.[752C > T; 761C > T] mutation
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positively correlated with serum CK levels (R = 0.629,
p = 0.002) (Fig. 4a) and negatively correlated with
Pompe-PEDI mobility normative scores (R = −0.770,
p < 0.001) (Fig. 4b).
Discussion
Summary of findings
To the best of our knowledge, detailed muscle MRI
studies have not been previously reported for IOPD. The
only report described pre-ERT findings in 6 IOPD pa-
tients who showed no signal changes on T1WIs and
T2WIs [18, 19]. Because we conducted prospective
monitoring of neonatally treated IOPD patients, the
present study represents the first report of the sequence
of selective muscle involvement, which featured early re-
versible or irreversible involvement of the quadriceps
that was followed by more extensive changes within the
thigh. However, all scans showed T2WI hyperintensity
lesions over the thigh. The gluteal and trunk muscles,
except the psoas muscle in NBS3, showed less severe
and slower involvement. The progressive atrophy of the
thigh muscles, as suggested by decreased muscle mass
and separation of the muscles, was obvious when the pa-
tients were examined at 5–6 years of age. Previous ob-
servations of impairments in muscle mobility, as
evaluated using the Pompe-PEDI at 4 years of age [6],
suggest that the MRI findings obtained in the present
study are relevant.
Patterns of thigh involvement
The results obtained for neonatally treated IOPD pa-
tients revealed unique patterns of quadriceps involve-
ment. In previous studies of juvenile- and adult-onset
patients, the first MRI changes involved the posterior
thigh and trunk muscles [12, 20, 21]. The rectus femoris






Fig. 1 Earliest muscle MRI changes in newborn patients with IOPD. a-d At 13 days of age, no significant signal changes in the thigh were revealed on
T1WIs (a) obtained from NBS14, with equivalent findings on T2WIs (b). However, significant signal changes were observed on STIR images (c, d), which
revealed hyperintensity, particularly in the vastus lateralis (arrowhead). e-h At 7 months of age, hyperintensity was noted in the anterior region of the
thigh muscles on T2WIs (G, asterisk) and STIR images (h, arrowhead) but not on T1WIs (e, f)
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adult patients. However, in the present study and in
childhood-onset patients [22], the involvement of trunk
muscles (except the psoas muscle) appeared at a later
age. The different patterns of involvement between
early-treated IOPD and LOPD patients might reflect the
variable efficacy of rhGAA in muscles at different devel-
opmental stages. In addition, the composition of muscle
fiber types differs between children and adults, particu-
larly the distribution and abundance of type 2b fibers
[23, 24], which are less responsive to rhGAA [25].
T2WI high intensity
The meaning of the high intensity observed on
T2WIs in the present study is intriguing. High inten-
sity on T2WIs might suggest fatty infiltration and
edema/inflammation, but STIR suppresses fat signals
and reveals only inflammation or edema [26]. There-
fore, we suspected that the T2WI-positive process in
the examined patients reflected edema or inflamma-
tion. In Duchenne muscular dystrophy (DMD), hyper-
intensity on T2WIs has been associated with muscle
injury, repair, and inflammation [27]. Because obvious
inflammation or necrosis is not commonly observed
in muscle biopsied from patients with Pompe disease,
the hyperintensity on T2WIs likely reflects edema.
Consistent with this hypothesis, a recent study of
muscle water content that was performed using quan-
titative nuclear MRI in adult Pompe patients demon-
strated that 32 % of all muscles exhibited an increase
in water content and that fatty degenerative changes
took place faster in these muscles [28]. The increased
water content might reflect cytosolic glycogen release
from lysosomes, as glycogen storage disease type V
patients similarly presented a slight increase in the in-
tensity of muscle on T2WIs [29, 30] without fat re-
placement. Another possible explanation for the
T2WI hyperintensity is denervation, which was de-
scribed in a recent publication regarding a less obvi-
ous T2 high intensity in Charcot-Marie-Tooth disease
1A [31]. However, the T2WI intensity changes in the
thigh were minimal compared to the changes in my-

































Fig. 2 Muscle MRI in neonatally treated infants and toddlers with IOPD. a T1WIs (left panel) and T2WIs (right panel) of thigh muscle MRI scans
obtained at 1 year of age from NBS10 (upper panel) and an age- and sex-matched control (lower panel) were compared. NBS10 presented
hyperintensity at the bilateral quadriceps, particularly the vastus intermedius, on T2WIs (asterisk) but not on T1WIs. In addition, increased fat in
the intramuscular fascia (between the vastus lateralis and rectus femoris) was also observed (arrow). b T1WIs (left panel) and T2WIs (right panel) of
thigh muscle MRI scans obtained at 3 years of age from NBS10 (upper panel) and an age- and sex-matched control (middle panel) were compared.
NBS10 presented hyperintensity at the bilateral vastus intermedius and less hyperintensity at the vastus lateralis on T2WIs (asterisk) but not on T1WIs,
showing a significant decrease compared with previous images obtained at 1 year of age. In addition, hyperintensity at the bilateral rectus
femoris (triangles) was clearly evident on both T1WIs and T2WIs. Increased fat in the intramuscular fascia (between the vastus lateralis and
rectus femoris) was also observed but had not progress (arrow)
















Fig. 3 (See legend on next page.)
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In the current study, the early-onset STIR and T2WI
hyperintensity were associated with normal T1WI inten-
sity (T1WI-negative), which could be reversible. In con-
trast, T2WI and STIR hyperintensity in the older
patients was associated with T1WI hyperintensity
(T1WI-positive) that was followed by a significant
decrease in muscle mass without obvious fatty replace-
ment; this pattern differs from that observed in juvenile-
and adult-onset Pompe disease patients. Differences in
muscle-remolding ability between toddlers and children
might explain the lack of fatty replacement before
muscle atrophy observed in the patients examined in the
present study.
Implications for management
Here, we demonstrated by MRI studies a slow progres-
sive myopathy in neonatally treated IOPD patients who
continued to receive rhGAA at labeled (20 mg/kg every
2 weeks) or double dosages (40 mg/kg every other week
or 20 mg/kg/qw). Only 2 patients, who also exhibited
the earliest treatment initiation times, showed decreased
muscle involvement at the last evaluation at 4 years of
age when on higher dosages. Previous studies in adults
have suggested a significant quantitative increase in
muscle bulk in the lower limbs [32] after only 6 months
of rhGAA treatment, but this increase was primarily ob-
served in the spared muscles. Because muscle involve-
ment in IOPD is more extensive than that in LOPD,
treatment should be initiated prior to the evolution of ir-
reversible muscle changes. We observed reversible
T2WI changes prior to 3 years of age. Although further
clarification such as correlation with muscle biopsy or
EMG findings is needed, this finding suggests that earl-
ier and more potent treatment might partially rescue
those muscles. A recent study using even higher dose of
rhGAA than our current usage suggests improvement in
survival and motor function outcomes in IOPD patients
[33], supporting our speculation.
Limitations of this study
This prospective, long-term follow-up cohort study was
conducted over a long period of time. Therefore, the
methods used to obtain the MRI scans could have varied
slightly, and different scanners were used. Thus, we used
the relative intensity to visualize hyperintensity signals
on MRIs. Second, because of time constraints and
anesthesia-related risks, we only scanned the trunk/pel-
vis/thighs under sedation. This method produced some
artifacts on the images because the patients were not
completely anesthetized. However, we did not observe
arrhythmia or other complications during this proced-
ure. Third, we used severity scores and not quantitative
measurements for the affected muscles. In the present
study, we aimed to describe the pattern of involvement
over time; therefore, the sensitivity of the severity scores
might not be a critical factor. Moreover, we followed a
small number of cases and acquired a low number of
images. Thus, a longer follow-up with more patients will
be necessary to confirm the observations reported here.
Conclusions
The results of the present study showed that muscle
MRI provides a non-invasive method to monitor
muscle damage in IOPD patients. Without persistent
antibody interference and neonatal initiation of ERT,
the muscles remain damaged and present with edema.
These symptoms are followed by slowly progressing
muscle atrophy and fatty infiltration and the eventual
loss of muscle function. Using a combination of MRI
techniques, muscle involvement can now be character-
ized in more detail. Future longitudinal studies that
complete serial examinations of muscles in IOPD pa-
tients would be valuable to extend the findings of the
present study and provide further information regard-
ing the treatment of IOPD.
Ethics, consent and permissions
All procedures followed were in accordance with the eth-
ical standards of the responsible committee on human ex-
perimentation (institutional and national) and with the
Declaration of Helsinki of 1975, as revised in 2000. The
Institutional Review Board approved this study, and writ-
ten informed consent was obtained from the parents of all
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Fig. 3 Sequential MRI studies in neonatally treated patients with IOPD. (a) Imaging of NBS4 was performed at 6 (left panel) and 8 years (right
panel) of age. Changes were most severe in the thigh muscles (arrowheads), followed by the trunk and pelvic muscles. STIR revealed the rapid
progression of hyperintensity over the quadriceps muscles. (a, f) Thigh T1WIs, (b, g) thigh T2WIs, (c, h) trunk T2WIs, (d, i) pelvic T2WIs, and (e, j)
coronal STIR images. Q: quadriceps muscles; P: psoas muscles. (b) Similar thigh T2WI changes in patients examined at 5 (a–c) and 8 years (d–f) of
age. T2WI signal changes and muscle atrophy were prominent, particularly over the quadriceps muscles in the IOPD patients but not in the LOPD
patients who were administered rhGAA therapy: (a, d) NBS2, (b, e) NBS3, and (c, f) NBSL2. (c) Variable degrees of thigh T2WI changes in patients
examined at 3 (a–c) and 5 years (d–f) of age. T2 signal changes over the quadriceps muscles and increased intramuscular fat were prominent the
IOPD patients but not in the LOPD patients who were administered rhGAA therapy: (a, d) NBS5, (b, e) NBS6, and (c, f) NBSL6
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Additional files
Additional file 1: Figure S1. Additional MRI findings in young patients.
At age 3, NBS12 (IOPD), NBSL16 (LOPD under ERT for 2.6 years) and
NBSL12 (LOPD without ERT) were compared. T1WIs (asterisk), T2WIs
(asterisk) and STIR images (arrow) revealed significant hyperintensity in
the vastus intermedius and vastus lateralis in NBS12 but not in NBSL16. In
NBSL12, slightly increased signals were observed in STIR images but not
T1WIs or T2WIs, but the quadriceps images showed increased
intramuscular fat, indicating less muscle mass. (BMP 3062 kb)
Additional file 2: Figure S2. Abdominal muscle involvement. All IOPD
patients (A-E) presented with thin rectus abdominis muscles (triangles)
and variable degrees of involvement of lateral muscles (transversus
abdominis and external and internal oblique muscles) compared with a
non-IOPD patient (F): (A) NBS3 at age 6 also demonstrated the atrophy of
psoas muscles (arrow); (B) NBS5 at age 5; (C) NBS6 at age 6; (D) NBS8 at
age 6; (E) NBS9 at age 4; and (F) NBSL6 at age 5. (BMP 730 kb)
Additional file 3: Figure S3. Early-onset psoas muscle atrophy. MRI
studies of patients NBS3 (A-D), NBS2 (E-G), and NBS12 (H-K) revealed
variable signal changes and psoas muscle atrophy: Q: quadriceps and P:
psoas. (BMP 1701 kb)
Additional file 4: Figure S4. Longitudinal follow-up of trunk, pelvic, and
thigh muscle MRI involvement severity scores. For each muscle, involvement
on T2WIs was scored from 1 (normal) to 4 (atrophy or total fat replacement).
Seven muscles were scored, and the sum was plotted. Two of the 10
patients demonstrated improvement in muscle involvement. Black filled
diamonds indicate the time under which the patients received a greater
than labeled rhGAA dosage. NBS8 and NBS11 were receiving a higher
dosage at the indicated time.
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Fig. 4 Correlations of trunk, pelvic, and thigh muscle MRI involvement
severity scores. The severity score was positively correlated with serum
CK levels (a) and negatively correlated with mobility function (b)
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